Overview

Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerated dose of NC-4016 that can be given to patients with advanced solid tumors or lymphoma. The safety of the drug will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
NanoCarrier Co., Ltd.
Collaborator:
M.D. Anderson Cancer Center
Treatments:
NC-4016